About Amal Therapeutics
AMAL Therapeutics SA is a spin-off from the University of Geneva
active in cancer immunotherapy.
AMAL has developed a unique protein-based immunization
platform called KISIMA® providing activation signal to dendritic
cells simultaneously to priming both helper and killer cells for
various antigens and HLA restrictions. This first-in-class platform is
offering the opportunity to develop standardized and indicationtailored
The company’s lead product ATP128 is currently being developed
for metastatic and advanced colorectal cancer.
State of Ownership